Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-11-12 |
Cellectis (France) |
€13 million |
private placement |
|
|
Private placement |
2014-11-10 |
Histide (Switzerland) |
CHF 4.5 Million (€3.7 million) |
series A financing round |
PARTER Capital Group (Switzerland) and a group of private investors |
|
Series A financing round |
2014-11-07 |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) |
$35 million |
private placement |
|
Cancer - Oncology |
Private placement |
2014-11-05 |
MDXHealth (Belgium) |
€ 12.33 million ($ 15.43 million) |
capital increase |
|
Cancer - Oncology - Diagnostic - Technology - Services |
Capital increase |
2014-11-05 |
Active Biotech (Sweden) |
|
capital increase |
|
Cancer - Oncology - Neurodegenerative diseases |
Capital increase |
2014-11-04 |
Mérieux Développement |
€ 150 million |
|
Institut Mérieux (France) Sienne Capital (Luxemburg) |
|
Private placement |
2014-10-30 |
Cortendo (Sweden) |
$11 million (NOK 73.4 million - € 8.62 million) |
private placement |
HealthCap (Sweden), Third Swedish National Pension Fund (AP3) (Sweden), Storebrand (Norway), Arctic Fund Management (Norway) |
Rare diseases |
Private placement |
2014-10-29 |
Bavarian Nordic (Denmark) |
DKK 250,999,997.35 (€ 33.7 million) |
capital increase |
Johnson & Johnson Development Corporation (USA - NJ) |
Infectious diseases |
Capital increase |
2014-10-28 |
DCPrime (The Netherlands) |
undisclosed |
financing round |
SkylineDx (The Netherlands), Van Herk Investments (The Netherlands) |
Cancer - Oncology |
Financing round |
2014-10-28 |
Imevax (Germany) |
€7.5 million |
series A financing round |
Wellington Partners (UK), BioMedPartners (Switzerland), EMBL Ventures (Germany), Santo Venture Capital (Germany) |
Infectious diseases |
Series A financing round |
2014-10-28 |
Advent Life Sciences (UK) |
£145.5 million (€184.7 million) |
fundraising |
|
|
Fundraising |
2014-10-27 |
Probiodrug (Germany) |
€ 22.5 million |
IPO |
|
Neurodegenerative diseases |
IPO |
2014-10-27 |
OPTIVAC projet led by Imaxio (France), the VirPath laboratory at the Université Claude Bernard of Lyon (France) and the International Center for Infectiology Research (CIRI) (France) |
€600,000 |
grant |
National Research Agency (France) |
Infectious diseases |
Grant |
2014-10-24 |
Oryzon Genomics (Spain) |
€ 1.1 million |
grant |
Ministry of Economy and Competitiveness of the Spanish Government (Spain) |
|
Grant |
2014-10-23 |
Erytech Pharma (France) |
€ 30 million |
capital increase |
|
Cancer - Oncology |
Capital increase |
2014-10-23 |
DBV Technologies (France) |
€ 90 million |
IPO |
|
Allergic diseases - Immunological diseases |
IPO |
2014-10-22 |
Hybrigenics (France) |
€4.62 million |
private placement |
Crede Capital Group (USA) |
Technology - Services - Cancer - Oncology |
Private placement |
2014-10-22 |
Tetraphase Pharmaceuticals (USA - MA) |
$86.3 million |
private placement |
|
Infectious diseases |
Private placement |
2014-10-20 |
Immupharma (UK) |
€400,000 |
grant |
region of Aquitaine (France) |
|
Grant |
2014-10-16 |
Epigenomics (Germany - USA - MD |
$ 5.3 million (€ 4.2 million) |
capital increase |
BioChain Institute (USA - CA) |
Cancer - Oncology - Diagnostic |
Capital increase |